

Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly

Evolving Trends Strategy

Expectations of Trump's pro-growth agenda drove positive market sentiment

- Global equities rose, led by the U.S., while Europe and China fell on trade concerns
- Solid earnings results season for Evolving Trends strategy supported performance
- Strength in the strategy's Healthcare exposure

Tom Riley & Gregg Bridger
Portfolio Managers, Evolving Trends Strategy

What's happening?

Global equities rose in November, with the MSCI ACWI gaining 3.7% in USD terms. The gains were led by the US, where the market responded positively to the election of President Donald Trump. Expectations are that the new administration will have a pro-growth agenda, with lower taxes and a more supportive regulatory backdrop.

European markets failed to participate in the market rally and European bourses sunk on worries about a trade war with the US, the region's largest trading partner. The main stock index, the Stoxx 600 Index, touched its lowest point in three months due to the combination of Trump's election and escalating geopolitical tensions.

Emerging market equities also fell, led by China, as Republican control of the White House and Congress risked heightened tensions over trade and technology. In response to the threat of additional trade barriers from the US, Beijing promised further stimulus packages to kickstart the economy, but this failed to allay investor concerns.

At the sector level, Consumer Discretionary performed strongly as post-election euphoria saw consumer confidence increase amid optimism around the labour market, expectations for lower inflation and higher stock prices. There was also a notable change was the change in leadership within the Technology sector, as Software companies began to materially outperform Semiconductor companies. The key reasons for the shift are lower perceived tariff risks and positive earnings revisions for software companies, plus continued inventory and cyclical challenges in parts of the semiconductor market.

Portfolio positioning and performance

The strategy performed broadly in line with the MSCI All Countries World Index over the month. Relative to the benchmark, the biggest single detractor came from not owning Tesla, which saw shares rise by almost 40% over the month as the market became optimistic about the influence of Elon Musk in the new Trump administration.

The Q3 earnings season has overall been positive for the Fund, particularly when contrasted with the broader market. At the time of writing (4 December 2024), 88% of companies held in the strategy that have reported earnings have beaten earnings expectations compared to 54% for the broader market as measured by the MSCI ACWI Index (source Bloomberg). Stock selection in Technology was a detractor- where our overweight to Semiconductors dragged as Software outperformed. Technology holdings in the Automation theme, such as Taiwan Semiconductor Manufacturing, Applied

Source: All data sourced from Bloomberg, local currencies, as at 30/11/2024

Materials and Advanced Micro Devices were all down during the month. Alibaba also dragged on performance as the optimism around a fiscal policy supported boost to Chinese consumption began to be replaced by concerns about tariffs.

In contrast, stock selection in Healthcare was positive. Notable contributions came from Globus Medical, who showed good cost control in their Q3 results, and Boston Scientific, which presented good clinical trial results for their left atrial appendage closure product.

Within the Ageing & Lifestyle theme, On Holdings continued to be a strong performer. In Q3 sales grew 32% year over year, ahead of market expectations of 29%. In addition to the impressive growth in their footwear business, ON are also growing their Apparel segment at 33%, suggesting that the brand's expansion into new product categories justifies the high valuation relative to peers.

Over the month we added to our position in Keyence, a high quality Japanese industrial technology company, on expectations that the market for industrial automation should improve in 2025.

Outlook

The macroeconomic backdrop is likely to remain mixed going into 2025, with the United States being the most advantaged region globally. While there are concerns around the impact of tariffs on the US economy, data suggests that the sensitivity has declined in recent years; around 24% of US imports came from China in 2018 and this has fallen to around 14% in 2024. The impact of tariffs may be challenging for some sectors, but there has already been a significant decoupling of Chinese and US supply chains in the post covid era. Support for US manufacturing and reshoring is likely and therefore we see a better industrial economy ahead in the US. The US manufacturing environment has been weak for almost 2 years now, and we anticipate that over the coming quarters we should see some of the impacts of the various Infrastructure acts start to boost activity levels. Whilst these acts were signed in to law some time ago, (Infrastructure Investment and Jobs Act in November 2021, Chips and Science Act in August 2022, Inflation Reduction Act in August 2022), relatively little of the allocated budget has been distributed and this support isn't anticipated to peak until 2026. This should be a benefit for many of the companies within our Automation theme going into 2025 and beyond.

While the market broadly recognised the opportunity for the Artificial Intelligence enablers in 2024, the potential productivity benefits that may be harnessed by software providers in various markets are starting to emerge. The fund is well positioned to capture this growth through our holdings in software companies that should be able to help their customers across sectors leverage the power of AI.

We believe that our thematic investment philosophy leads us to find companies that will benefit from evolution and disruption across sectors.

No assurance can be given that the Evolving Trends Strategy will be successful. Investors can lose some or all of their capital invested. The Evolving Trends strategy is subject to risks including Equity; Emerging markets; Currency; Global investments; Investments in small and/or micro capitalisation universe; ESG.

Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Source: All data sourced from Bloomberg, local currencies, as at 30/11/2024

Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short-term holding.

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions, and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 7 Newgate Street, London EC1A 7NX. In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.

In Hong Kong, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document is to be used only by persons defined as "professional investor" under Part 1 of Schedule 1 to the Securities and Futures Ordinance (SFO) and other regulations, rules, guidelines, or circulars which reference "professional investor" as defined under Part 1 of Schedule 1 to the SFO. This document must not be relied upon by retail investors. Circulation must be restricted accordingly.

In Singapore, this document is issued by AXA Investment Managers Asia (Singapore) Ltd. (Registration No. 199001714W) and is intended for the use of Institutional Investors only as defined in Section 4A of the Securities and Futures Act (Cap. 289) and must not be relied upon by retail investors. Circulation must be restricted accordingly.

For Japanese clients: AXA Investment Managers Japan Ltd., whose registered office and principal place of business is at NBF Platinum Tower 14F 1-17-3 Shirokane, Minato-ku, Tokyo 108-0072, Japan, which is registered with the Financial Services Agency of Japan under the number KANTOZAIMUKYOKUCHO (KINSHO) 16, and is a member of Japan Securities Dealers Association, Type II Financial Instrument Firms Association, Investment Trust Association of Japan and Japan Investment Advisors Association to carry out the regulated activity of Financial Instrument Business under the Financial Instrument Exchange Law of Japan. In Japan, none of the funds mentioned in this document are registered under the Financial Instrument Exchange Law of Japan or Act on Investment Trusts and Investment Corporations. This document is purely for the information purpose for use by Qualified Institutional Investors defined by the Financial Instrument Exchange Law of Japan.

In Taiwan, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document and the information contained herein are intended for the use of professional or institutional investors and should not be relied upon by retail investors. They have been prepared and issued for private informational and educational purposes only at the sole request of the specified recipients, and not intended for general circulation. They are strictly confidential, and must not be reproduced, circulated, distributed, redistributed or otherwise used, in whole or in part, in any way without the prior written consent of AXA IM Asia. They are not intended for distribution to any persons or in any jurisdictions for which it is prohibited.

If any fund is highlighted in this communication (the "Fund"), its offering document or prospectus contains important information on selling restrictions and risk factors, you should read them carefully before entering into any transaction. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. AXA IM Asia does not intend to offer any Fund in any country where such offering is prohibited.

The offer, distribution, sale or re-sale of fund units/shares in Taiwan requires approval from and/or registration with Taiwanese regulatory authorities. To the extent that any units/shares of the Funds are not so licensed or registered, such units/shares are made available in Taiwan on a private placement basis only to banks, bills houses, trust enterprises, financial holding companies and other qualified entities or institutions (collectively, "Qualified Institutions") and other entities and individuals meeting specific criteria ("Other Qualified Investors") pursuant to the private placement provisions of the Rules Governing Offshore Funds. No other offer or sale of such units/shares in Taiwan is permitted. Taiwanese purchasers of such units/shares may not sell or otherwise dispose of their holdings except by redemption, transfer to a Qualified Institution or Other Qualified Investor, transfer by operation of law or other means approved by the Taiwan Financial Supervisory Commission.

In Korea, AXA Investment Managers Asia (Singapore) Ltd is a registered Cross Border Investment Advisor/Discretionary Investment Management Company under the Financial Investment Services and Capital Markets Act (the "Act"). The activities referenced under the Act are 5-2-2 Investment Advisory Business and 6-2-2 Discretionary Investment Management Business, respectively. Its financial services are available in Korea only to Professional Investors within the meaning of Article 10 of Enforcement Decree of the Financial Investment Services and Capital Markets Act.

To the extent that any fund is mentioned in this document, neither the fund nor AXA IM Asia is making any representation with respect to the eligibility of any recipients of this document to acquire the units/shares in the fund under the laws of Korea, including but without limitation the Foreign Exchange Transaction Act and Regulations thereunder. The units/shares have not been registered under the Financial Investment Services and Capital Markets Act of Korea, and none of the units/shares may be offered, sold or delivered, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to applicable laws and regulations of Korea.

For Malaysian investors: As the recognition by the Malaysian Securities Commission pursuant to Section 212 of the Malaysian Capital Markets and Services Act 2007 has not been / will not be obtained nor will this document be lodged or registered with the Malaysian Securities Commission, the shares referred to

Source: All data sourced from Bloomberg, local currencies, as at 30/11/2024

hereunder (if any) are not being and will not be deemed to be issued, made available, offered for subscription or purchase in Malaysia and neither this document nor any other document or other material in connection therewith should be distributed, caused to be distributed or circulated in Malaysia.

For Thailand investors: Nothing in this document shall constitute in any manner whatsoever a proposal to make available, offer for subscription or purchase or to issue an invitation to purchase or subscribe for any securities in Thailand or a proposal to implement any of the foregoing in Thailand nor has this document been approved by or registered with the Securities and Exchange Commission of Thailand ("SEC"). No person receiving a copy of this document may treat the same as constituting an invitation or offer to him in Thailand and such person shall not distribute or make available this document in Thailand. The issuer of this document shall not be liable in any manner whatsoever in the event this document is distributed or made available to any person in Thailand receiving a copy of this document. Since no application for approval has been or will be made to the SEC for the offering of the securities, or for the registration of this document, the securities shall not be offered for subscription or purchased or made available, whether directly or indirectly, in Thailand. It is the sole responsibility of recipients wishing to take any action upon this document to satisfy themselves as to the full observance of the laws of Thailand, to comply with all relevant government and regulatory approvals, and to comply with all applicable laws, including but not limited to exchange control laws.

For Investors in People's Republic of China (PRC): This document does not constitute a public offer of the product, whether by sale or subscription in the PRC. The product is not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the product or any beneficial interest herein without obtaining all prior PRC's governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions.

MSCI: Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.